Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?

Yang, Panpan; Mao, Kuanzheng; Yuan-fu, Gao; Wang, Zhen; Wang, Jun; Chen, Yufei; C, Ma; Bian, Yun; Shao, Chengwei; Lu, Jianping

doi:10.1186/s40644-023-00528-z

Cited by 4 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly to MDCT, MRI utilizes time-contrast images to visualize the arterial and portal venous anatomy. Yang et al [88] showed that MRI and CT have similar performance in assessing PDAC tumor size before and after NAT. However, dynamic MRI is not commonly performed and should only be attempted by experienced centers due to difficulties in reproducibility and standardization [89].…”

Section: Resectability After Nat/nacrtmentioning

confidence: 99%

Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor

Pedrazzoli

2023

JCM

View full text Add to dashboard Cite

Background: Previously considered inoperable patients (borderline resectable, locally advanced, synchronous oligometastatic or metachronous pancreatic adenocarcinoma (PDAC)) are starting to become resectable thanks to advances in chemo/radiotherapy and the reduction in operative mortality. Methods: This narrative review presents a chosen literature selection, giving a picture of the current state of treatment of these patients. Results: Neoadjuvant therapy (NAT) is generally recognized as the treatment of choice before surgery. However, despite the increased efficacy, the best pathological response is still limited to 10.9–27.9% of patients. There are still limited data on the selection of possible NAT responders and how to diagnose non-responders early. Multidetector computed tomography has high sensitivity and low specificity in evaluating resectability after NAT, limiting the resection rate of resectable patients. Ca 19-9 and Positron emission tomography are giving promising results. The prediction of early recurrence after a radical resection of synchronous or metachronous metastatic PDAC, thus identifying patients with poor prognosis and saving them from a resection of little benefit, is still ongoing, although some promising data are available. Conclusion: In conclusion, high-level evidence demonstrating the benefit of the surgical treatment of such patients is still lacking and should not be performed outside of high-volume centers with interdisciplinary teams of surgeons and oncologists.

show abstract

Section: Resectability After Nat/nacrtmentioning

confidence: 99%

Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor

Pedrazzoli

2023

JCM

View full text Add to dashboard Cite

show abstract

Is it time to move from the Unidimensional RECIST 1.1 Response Assessment Criteria to a Volumetric Evaluation in the Present Era of Image-based Oncology? An Evaluation in Locally Advanced Head Neck Cancers Undergoing Treatment

Kale,

Datta,

Kalbande

et al. 2024

Clinical Oncology

View full text Add to dashboard Cite

Values of apparent diffusion coefficient in pancreatic cancer patients receiving neoadjuvant therapy

Chen,

Ma,

Yang

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background To investigate the values of apparent diffusion coefficient (ADC) for the treatment response evaluation in pancreatic cancer (PC) patients receiving neoadjuvant therapy (NAT). Methods This study included 103 NAT patients with histologically proven PC. ADC maps were generated using monoexponential diffusion-weighted imaging (b values: 50, 800 s/mm 2 ). Tumors’ minimum, maximum, and mean ADCs were measured and compared pre- and post-NAT. Variations in ADC values measured between pre- and post-NAT completion for NAT methods (chemotherapy, chemoradiotherapy), tumor locations (head/neck, body/tail), tumor regression grade (TRG) levels (0–2, 3), N stages (N0, N1/N2) and tumor resection margin status (R0, R1), were further analyzed. Results The minimum, maximum, and mean ADC values all increased dramatically after NAT, rising from 23.4 to 25.4% (all p < 0.001): mean (average: 1.626 × 10 − 3 mm 2 /s vs. 1.315 × 10 − 3 mm 2 /s), minimum (median: 1.274 × 10 − 3 mm 2 /s vs. 1.034 × 10 − 3 mm 2 /s), and maximum (average: 1.981 × 10 − 3 mm 2 /s vs. 1.580 × 10 − 3 mm 2 /s). The ADCs between the subgroups of all the criteria under investigation did not differ significantly for the minimum, maximum, or mean values pre- or post-NAT ( P = 0.08 to 1.00). In the patients with borderline resectable PC ( n = 47), the rate of tumor size changes after NAT was correlated with the pre-NAT mean ADC values (Spearman’s coefficient: 0.288, P = 0.049). Conclusions The ADC values of PC increased significantly following NAT; however, the percentage increases failed to provide any predictive value for the resection margin status or TRG levels.

show abstract

Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?

Cited by 4 publications

References 32 publications

Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor

Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor

Is it time to move from the Unidimensional RECIST 1.1 Response Assessment Criteria to a Volumetric Evaluation in the Present Era of Image-based Oncology? An Evaluation in Locally Advanced Head Neck Cancers Undergoing Treatment

Values of apparent diffusion coefficient in pancreatic cancer patients receiving neoadjuvant therapy

Contact Info

Product

Resources

About